No Data
Orient: The market prospects for lipid-lowering drugs are broad, with new targets and new technological routes continually being validated.
Due to the rising incidence of dyslipidemia, which is increasingly affecting younger populations, the market for lipid-lowering drugs has a broad outlook. At the same time, new targets and new technological routes are being continuously validated, and the approval of Innovative Drugs can also drive rapid market expansion.
Hong Kong stock movement | JUNSHI BIO (01877) surged over 5% as its anti-PD-1 monoclonal antibody combination therapy was included in the CDE breakthrough therapy list.
JUNSHI BIO (01877) rose over 5%, as of the time of reporting, it increased by 5.37%, priced at 12.16 Hong Kong dollars, with a transaction volume of 18.0543 million Hong Kong dollars.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
[Hong Kong Stock Connect] JUNSHI BIO (01877) rises by 5.5% AWT020 injection sterile powder clinical trial application approved.
Kingwo Financial News | JUNSHI BIO (01877) stock price has risen, sustaining high levels in the afternoon. As of the time of writing, it reported 11.5 Hong Kong dollars, up 5.5%, with a transaction amount of 14.3942 million Hong Kong dollars. JUNSHI BIO announced that it recently received the "Pharmaceutical Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the clinical trial application for AWT020 injection sterile powder (project code "JS213"). JS213 is a PD-1 and interleukin-2 bifunctional antibody fusion protein primarily used for the treatment of advanced malignant tumors.
Shanghai Junshi Biosciences Gets Clinical Trial Approval for Anti-tumor Drug; Shares Up 3%
Hong Kong Stock Announcement to Explore Opportunities | Aimei Vaccine: mRNA RSV vaccine shows significantly higher humoral immunity and cellular immunity than internationally marketed products, and has applied for clinical trials in the USA.
HBM HOLDINGS-B (02142): The HBM9378/SKB378 for the treatment of chronic obstructive pulmonary disease has been approved for IND permission by the NMPA; HENLIUS (02696): The European Commission has approved the use of Surulimab injection in combination with chemotherapy for first-line treatment in adult patients with extensive-stage small cell lung cancer.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
